拉米夫定是首个用于治疗慢性乙型肝炎的核苷类药物,至今已有十余年历史,该药对延缓慢性乙型肝炎患者疾病的进展起明显作用,但长期应用拉米夫定治疗过程中耐药性的产生大大降低了该药的长期疗效。意大利Lampenico教授于2007年9月23日在上海用详实的数据向国内专家介绍了最近有关拉米夫定耐药治疗的新概念,特别是有关联合治疗还是单药治疗的问题上,改变了过去的看法。一、出现耐药的动态变化 Lamivudine is the first nucleoside drug used to treat chronic hepatitis B and has been in existence for more than ten years. The drug has a significant effect on delaying the progression of the disease in patients with chronic hepatitis B. However, long-term use of Lamivudine Given the course of treatment of drug resistance greatly reduced the long-term efficacy of the drug. On September 23, 2007, Prof. Lampenico in Shanghai briefed domestic experts on the recent new concepts of resistance to lamivudine, in particular with regard to combination therapy or monotherapy, with detailed data in Shanghai that changed the past the opinion of. First, the emergence of dynamic changes in resistance